Skip to content
Evigrade
CriticalSNRI×Antidepressants. Other antidepressants of herbal origin

Updated · Methodology

Mechanism

St John's wort extract inhibits the synaptosomal reuptake of serotonin, noradrenaline and dopamine (St John's wort summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1), and duloxetine inhibits serotonin and noradrenaline reuptake. The interaction table of the St John's wort SmPC lists increased serotonergic effects and a higher incidence of adverse reactions with duloxetine (St John's wort SmPC, AEMPS, section 4.5). The duloxetine SmPC also states that adverse reactions may be more common with St John's wort and lists it among serotonergic agents (duloxetine SmPC, European Medicines Agency, EMA, sections 4.4 and 4.5). There is also a second route: St John's wort induces the enzyme CYP1A2 (St John's wort SmPC, AEMPS, section 4.5), and in the liver CYP1A2 and CYP2D6 convert duloxetine to inactive metabolites (duloxetine SmPC, EMA, section 5.2). Smokers, in whom CYP1A2 is induced, have duloxetine plasma levels almost 50% lower (duloxetine SmPC, EMA, section 4.5). The documents give no data on how St John's wort changes them.

Symptoms

According to the duloxetine label of the US Food and Drug Administration (FDA), St John's wort increases the risk of serotonin syndrome, a potentially life-threatening condition. Signs include mental status changes (agitation, hallucinations, delirium, coma), autonomic instability (tachycardia, labile blood pressure, dizziness, sweating, flushing, hyperthermia), neuromuscular symptoms (tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, nausea, vomiting and diarrhoea (FDA duloxetine label, section 5.4). In its most severe form the syndrome can resemble neuroleptic malignant syndrome, with fever, muscle rigidity, raised serum creatine kinase, rapid fluctuation of vital signs and mental status changes (duloxetine summary of product characteristics, European Medicines Agency, EMA, section 4.4).

Management

The Spanish St John's wort summary of product characteristics (SmPC) contraindicates the combination: St John's wort must not be used with antidepressants, and its interaction table names duloxetine (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). The authorisation of this product has been suspended since 11 June 2026, and there is no other current Spanish St John's wort SmPC. The duloxetine SmPC is less strict and recommends caution when duloxetine is used with St John's wort (duloxetine SmPC, European Medicines Agency, EMA, section 4.5). If the two have nevertheless been taken together, observe the patient carefully for signs of serotonin syndrome, particularly at the start of treatment and after dose increases (duloxetine SmPC, EMA, section 4.4; duloxetine label, US Food and Drug Administration, FDA, section 7.14). If serotonin syndrome occurs, consider stopping duloxetine and/or the other serotonergic medicines (FDA duloxetine label, section 7.14). No document says how long to wait between stopping St John's wort and starting duloxetine. Increased enzyme activity returns to normal within 1 week of stopping St John's wort (St John's wort herbal monograph, EMA, section 4.5).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Duloxetine

Other interactions with Hypericum perforatum